Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies

BACKGROUND: In 2007, Omnitrope® was the first biosimilar recombinant human growth hormone (rhGH) to be approved in Sweden for treatment in adults and children. Over 10 years’ safety and effectiveness data for biosimilar rhGH can now be presented. METHODS: PATRO Children and PATRO Adults are multicen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundberg, Elena, Kriström, Berit, Zouater, Hichem, Deleskog, Anna, Höybye, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191769/
https://www.ncbi.nlm.nih.gov/pubmed/32349731
http://dx.doi.org/10.1186/s12902-020-0535-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191769/
https://www.ncbi.nlm.nih.gov/pubmed/32349731
http://dx.doi.org/10.1186/s12902-020-0535-4

Ejemplares similares